Astragaloside IV

SKU: orb1304786

Description

Astragaloside IV is a bioactive saponin from Astragalus membranaceus with broad research applications. It exhibits anti-cancer activity in vitro by inhibiting ERK/JNK signaling and MMPs in MDA-MB-231 cells, and demonstrates cardioprotective effects in vivo, reducing infarct size in canine models. It also shows antiviral activity against HAdV-3 replication in A549 cells.

Research Area

Metabolism Research, Protein Biochemistry, Signal Transduction

Key Properties

• CAS Number: 84687-43-4
• MW: 784.97
• Purity: 98.85%
• Formula: C₄₁H₆₈O₁₄
• SMILES: CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]1[C@H](O)C[C@@]2(C)C3C[C@@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C4[C@]5(CC35CC[C@]12C)CCC(O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C
• Target: JNK,MMP,Estrogen/progestogen Receptor,ERK
• Solubility: DMSO:100 mg/mL (127.39 mM)

Bioactivity

• In Vivo:
  In a mice model, astragaloside IV administration at high doses significantly improved 48-hour survival rates (60% vs 13.3%, P < 0.05), markedly decreased serum levels of ALT and AST (P < 0.01), and substantially mitigated liver histopathological indices and hepatocyte apoptosis (P < 0.01). Furthermore, it significantly reduced MDA content in liver homogenates (P < 0.01) while enhancing SOD activity. Oral doses of astragaloside IV (10, 20 mg/kg) notably prevented cognitive deficits following transient cerebral ischemia and reperfusion. Both doses effectively reduced cytokine levels when compared to the Model group. Additionally, astragaloside IV markedly suppressed TLR4 levels and its downstream proteins, underlining the significance of the MyD88-dependent and -independent pathways in its anti-inflammatory action. It also decreased the expression of NLRP3 and cleaved-caspase-1, alongside reducing Iba1 protein expression, further evidencing its therapeutic potential in inflammation-related pathologies.
• In Vitro:
  Astragaloside IV reduces the viability and invasiveness of MDA-MB-231 breast cancer cells by impeding the activation of mitogen-activated protein kinase (MAPK) family members ERK1/2 and JNK and lowers the expression of matrix metalloproteases (MMP)-2 and -9. At concentrations of 10, 20, and 40 ng/mL, it hampers the growth of NSCLC cells, while lower doses (1, 2.5, 5 ng/mL) exhibit negligible cytotoxic effects. Additionally, when used alongside cisplatin, astragaloside IV notably enhances the chemosensitivity of NSCLC cells. This synergistic effect is further evidenced by the significant reduction in mRNA and protein levels of B7-H3 during combined treatment with astragaloside IV and cisplatin.
• Cell Research:
  CCK-8 assay is adopted to determine cell viability. cultured NSCLC cells are seeded into 96-well plates at the density of 4×104 (cells/well). Then 10 μL well CCK8 solution is added and incubated in dark at 37°C for another 2 h. The absorbance is determined with the wavelength of 490 nm.
• Animal Research:
  Transient cerebral ischemia and reperfusion is prepared by BCCAO. Mice are randomly divided into the Sham, Model, Astragaloside IV (10 mg/kg) and Astragaloside IV (20 mg/kg) treatment groups. The Astragaloside IV treatment groups are intragastrically administered 7 days before the surgery and terminated on the day of sacrifice. On the day of the surgery, Astragaloside IV is administrated 2 h prior to ischemia. The Sham-operated and Model groups are treated with distilled water. After the mice are anesthetized with an intraperitoneal injection of chloral hydrate (350 mg/kg), the bilateral common carotid arteries are exposed and carefully separated with a small ventral neck incision and occluded twice (20 min each) with ligated surgical silk as described previously with minor modifications. There is a 10 min reperfusion period between the two occlusion periods (ischemia 20 min reperfusion 10 min ischemia 20 min). Sham-operated mice are subjected to the same surgical operation without the surgical silk ligation. Mouse body temperature is maintained at 37±0.5°C during the surgery with heating equipment until recovery from the anesthesia.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

AS-IV, Astragaloside IV, AST-IV, Matrix metalloproteinases, ERS, ERK, Extracellular signal regulated kinases, Estrogen Receptor, EstrogenReceptor, MMP, Inhibitor, inhibit, JNK, progestogen Receptor, progestogenReceptor

Compound Identifiers

PubChem CID

158694